5-(5H-dibenzo[a,d]cyclohepten-5-yl)-4-thiouridine | 214481-38-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 二苯并环庚烯
• 英文名称: 5-(5H-dibenzo[a,d]cyclohepten-5-yl)-4-thiouridine
• 英文别名: 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-sulfanylidene-5-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenyl)pyrimidin-2-one
• CAS: 214481-38-6
• 化学式: C₂₄H₂₂N₂O₅S
• 分子量: 450.515
• InChiKey: FXCUYHQWYSLSAA-KTDPBYDISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  32
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  134
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-(5H-dibenzo[a,d]cyclohepten-5-yl)-4-thiouridine 、 氯屈瞵酸 在 磷酸三乙酯 、 三氯氧磷 、 三正丁胺 作用下， 生成
  参考文献：
  名称：

  From UTP to AR-C118925, the discovery of a potent non nucleotide antagonist of the P2Y2 receptor

  摘要：

  The G protein-coupled P2Y(2) receptor, activated by ATP and UTP has been reported as a potential drug target for a wide range of important clinical conditions, such as tumor metastasis, kidney disorders, and in the treatment of inflammatory conditions. However, pharmacological studies on this receptor have been impeded by the limited reported availability of stable, potent and selective P2Y(2)R antagonists. This article describes the design and synthesis of AR-C118925, a potent and selective non-nucleotide antagonist of the P2Y(2) receptor discovered using the endogenous P2Y(2)R agonist UTP as the chemical starting point. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2017.09.043
• 作为产物：
  描述：

  5-二苯并环庚烯酮 在 三乙基硅烷 、 四甲基乙二胺 、 三氟化硼乙醚 、 仲丁基锂 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 5-(5H-dibenzo[a,d]cyclohepten-5-yl)-4-thiouridine
  参考文献：
  名称：

  From UTP to AR-C118925, the discovery of a potent non nucleotide antagonist of the P2Y2 receptor

  摘要：

  The G protein-coupled P2Y(2) receptor, activated by ATP and UTP has been reported as a potential drug target for a wide range of important clinical conditions, such as tumor metastasis, kidney disorders, and in the treatment of inflammatory conditions. However, pharmacological studies on this receptor have been impeded by the limited reported availability of stable, potent and selective P2Y(2)R antagonists. This article describes the design and synthesis of AR-C118925, a potent and selective non-nucleotide antagonist of the P2Y(2) receptor discovered using the endogenous P2Y(2)R agonist UTP as the chemical starting point. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2017.09.043

文献信息

• [EN] NOVEL PHOSPHATE COMPOUNDS AND THEIR USE AS MEDICAMENTS<br/>[FR] NOUVEAUX COMPOSES DE PHOSPHATE ET LEUT UTILISATION COMME MEDICAMENTS
  申请人：ASTRA PHARMACEUTICALS LTD.

  公开号：WO1998045309A1

  公开（公告）日：1998-10-15

  (EN) The invention provides novel phosphate derivatives, processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of inflammatory conditions.(FR) L'invention concerne de nouveaux dérivés de phosphate, leurs procédés de préparation, des compositions pharmaceutiques les contenant et leur utilisation pour le traitement d'états inflammatoires.

  该发明提供了新型磷酸盐衍生物，其制备方法，包含它们的药物组合物以及它们在治疗炎症状况方面的应用。
• Phosphate compounds and their use as medicaments
  申请人：Astra Pharmaceuticals Ltd.

  公开号：US05985849A1

  公开（公告）日：1999-11-16

  A compound of the formula (I) or salts thereof: ##STR1## wherein X, R.sup.1, Q.sup.1 and Q.sup.2 are as defined in the specification. The compounds have been found to be P2 7-TM G-protein receptor antagonists, especially to the P2 Y2 receptor, and are useful in therapy, for example as anti-inflammatory agents useful in the treatment of a number of inflammatory diseases such as asthma, inflammatory bowel disease, ARDS, psoriasis, rheumatoid arthritis, myocardial ischaemia, COPD, cystic fibrosis, arthrosclerosis, restenosis, peridontal disease, septic shock, osteoarthritis and stroke.

  化合物的公式(I)或其盐：##STR1## 其中X，R.sup.1，Q.sup.1和Q.sup.2如说明书中所定义。已发现这些化合物是P2 7-TM G蛋白质受体拮抗剂，特别是对P2Y2受体，可用于治疗，例如作为抗炎药物用于治疗多种炎症性疾病，如哮喘，炎症性肠病，ARDS，牛皮癣，类风湿性关节炎，心肌缺血，COPD，囊性纤维化，动脉硬化，再狭窄，牙周病，感染性休克，骨关节炎和中风。
• NOVEL PHOSPHATE COMPOUNDS AND THEIR USE AS MEDICAMENTS
  申请人：Astra Pharmaceuticals Limited

  公开号：EP0973789A1

  公开（公告）日：2000-01-26
• US5985849A
  申请人：——

  公开号：US5985849A

  公开（公告）日：1999-11-16
• From UTP to AR-C118925, the discovery of a potent non nucleotide antagonist of the P2Y2 receptor
  作者：Nicholas Kindon、Andrew Davis、Iain Dougall、John Dixon、Timothy Johnson、Iain Walters、Steve Thom、Kenneth McKechnie、Premji Meghani、Michael J. Stocks

  DOI：10.1016/j.bmcl.2017.09.043

  日期：2017.11

  The G protein-coupled P2Y(2) receptor, activated by ATP and UTP has been reported as a potential drug target for a wide range of important clinical conditions, such as tumor metastasis, kidney disorders, and in the treatment of inflammatory conditions. However, pharmacological studies on this receptor have been impeded by the limited reported availability of stable, potent and selective P2Y(2)R antagonists. This article describes the design and synthesis of AR-C118925, a potent and selective non-nucleotide antagonist of the P2Y(2) receptor discovered using the endogenous P2Y(2)R agonist UTP as the chemical starting point. (C) 2017 Elsevier Ltd. All rights reserved.